Why the study?
SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular death, but Hispanic/Latino patients and methamphetamine users have been under-represented in prior studies.
Do SGLT2 inhibitors improve cardiovascular outcomes in an ethnically diverse heart failure population, including methamphetamine users?
Population
413 heart failure patients in Central Valley, California, 72% non-White, 27% methamphetamine users
Comparison
Outcomes before and after starting SGLT2 inhibitors
Design
Retrospective cohort study
Follow-up
12 months
Key result
Among 413 ethnically diverse patients with heart failure, the composite CV outcome occurred in 20.8% within 12 months of starting an SGLT2 inhibitor.
Authors
Loading...
May inform real-world expectations in diverse HF populations; extends RCT data to ethnic minorities and methamphetamine users but remains hypothesis-generating.
Cohort (n=413)
Do SGLT2 inhibitors improve cardiovascular outcomes in an ethnically diverse heart failure population, including methamphetamine users?
SGLT2 inhibitors are associated with reduced heart failure hospitalizations at 1 year in a diverse real-world cohort, though methamphetamine use, prior HFH, and reduced LVEF remain strong predictors of adverse cardiovascular outcomes.
Lee et al. (2026) conducted a cohort in Heart failure (n=413). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) was evaluated on Composite CV outcome. Among 413 ethnically diverse patients with heart failure, the composite CV outcome occurred in 20.8% within 12 months of starting an SGLT2 inhibitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: